Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 3, Issue 1
  5. Article
Volume 3, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), formerly known as Non-alcoholic fatty liver disease (NAFLD), is characterized by fat accumulation in the liver and is associated with obesity, insulin resistance, and metabolic syndrome. Early detection and intervention are crucial to prevent disease progression to advanced fibrosis, cirrhosis, and liver failure. Non-invasive tests like transient elastography (TE), the Fibrosis-4 (FIB-4) index, the Enhanced Liver Fibrosis (ELF) score, and magnetic resonance imaging (MRI) are safer and more convenient than invasive procedures like liver biopsy for detecting advanced fibrosis in MAFLD patients. Agile 3+ is a non-invasive test that combines liver stiffness measurement (LSM) with clinical and laboratory findings to detect advanced fibrosis in MAFLD patients. It has shown high accuracy in detecting advanced fibrosis in MAFLD patients. The combination of LSM and laboratory findings provides a more accurate assessment of disease severity, making Agile 3+ a reliable, non-invasive test for assessing liver fibrosis in MAFLD patients. In summary, MAFLD is a common condition that can progress to advanced fibrosis and liver failure if left untreated. Non-invasive tests such as Agile 3+ have emerged as valuable tools for detecting advanced fibrosis in MAFLD patients, providing a more accurate assessment of disease severity and making it a reliable non-invasive test for assessing liver fibrosis in MAFLD patients

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906302851240604042954
2024-06-27
2025-01-19

  • From This Site

    /content/journals/ijghd/10.2174/0126662906302851240604042954
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MokhtareM. AbdiA. SadeghianA.M. SotoudeheianM. NamaziA. Khalighi SikaroudiM. Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the Mediterranean diet.Clin. Nutr. ESPEN20235822122710.1016/j.clnesp.2023.10.001 38057010
     [Google Scholar]
  2. MokhtareM. SadeghianA.M. SotoudeheianM. S1390 the accuracy and reliability of AST to platelet ratio index, FIB-4, FIB-5, and NAFLD fibrosis scores in detecting advanced fibrosis in patients with metabolic-associated fatty liver disease.Am. J. Gastroenterol.2023118S1064S5
     [Google Scholar]
  3. LimG.E.H. TangA. NgC.H. ChinY.H. LimW.H. TanD.J.H. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD.Clinical Gastroenterology and Hepatology20232161962910.1016/j.cgh.2021.11.038
     [Google Scholar]
  4. LiuJ. AyadaI. ZhangX. WangL. LiY. WenT. MaZ. BrunoM.J. de KnegtR.J. CaoW. PeppelenboschM.P. GhanbariM. LiZ. PanQ. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults.Clin. Gastroenterol. Hepatol.2022203e573e58210.1016/j.cgh.2021.02.030 33618024
     [Google Scholar]
  5. ZiamaneshF. MohammadiM. EbrahimpourS. Tabatabaei-MalazyO. MosallanejadA. LarijaniB. Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review.J. Diabetes Metab. Disord.20232221083109410.1007/s40200‑023‑01293‑3 37975107
     [Google Scholar]
  6. MastromauroC. PolidoriN. GianniniC. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes.Curr. Opin. Pediatr.202234441442210.1097/MOP.0000000000001138 35836399
     [Google Scholar]
  7. GoftonC. UpendranY. ZhengM.H. GeorgeJ. MAFLD: How is it different from NAFLD?Clin. Mol. Hepatol.202329Suppl.S17S3110.3350/cmh.2022.0367 36443926
     [Google Scholar]
  8. MantovaniA. MAFLD vs. NAFLD: Where are we?Dig. Liver Dis.202153101368137210.1016/j.dld.2021.05.014 34108096
     [Google Scholar]
  9. NguyenV.H. LeM.H. CheungR.C. NguyenM.H. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD.Clinical Gastroenterology and Hepatology20211921722181
     [Google Scholar]
  10. LinS. HuangJ. WangM. KumarR. LiuY. LiuS. WuY. WangX. ZhuY. Comparison of MAFLD and NAFLD diagnostic criteria in real world.Liver Int.20204092082208910.1111/liv.14548 32478487
     [Google Scholar]
  11. FouadY. ElwakilR. ElsahharM. SaidE. BazeedS. Ali GomaaA. HashimA. KamalE. MehrezM. AttiaD. The NAFLD‐MAFLD debate: Eminence vs evidence.Liver Int.202141225526010.1111/liv.14739 33220154
     [Google Scholar]
  12. YounossiZ.M. RinellaM.E. SanyalA.J. HarrisonS.A. BruntE.M. GoodmanZ. CohenD.E. LoombaR. From NAFLD to MAFLD: Implications of a premature change in terminology.Hepatology20217331194119810.1002/hep.31420 32544255
     [Google Scholar]
  13. YamamuraS. EslamM. KawaguchiT. TsutsumiT. NakanoD. YoshinagaS. TakahashiH. AnzaiK. GeorgeJ. TorimuraT. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.Liver Int.202040123018303010.1111/liv.14675 32997882
     [Google Scholar]
  14. BiancoC. RomeoS. PettaS. LongM.T. ValentiL. MAFLD vs NAFLD: Let the contest begin!Wiley Online Library202020792081
     [Google Scholar]
  15. KuchayM.S. ChoudharyN.S. MishraS.K. Pathophysiological mechanisms underlying MAFLD.Diabetes Metab. Syndr.20201461875188710.1016/j.dsx.2020.09.026 32998095
     [Google Scholar]
  16. BoccatondaA. AndreettoL. D’ArdesD. CoccoG. RossiI. VicariS. SchiavoneC. CipolloneF. GuagnanoM.T. From NAFLD to MAFLD: Definition, pathophysiological basis and cardiovascular implications.Biomedicines202311388310.3390/biomedicines11030883 36979861
     [Google Scholar]
  17. SakuraiY. KubotaN. YamauchiT. KadowakiT. Role of insulin resistance in MAFLD.Int. J. Mol. Sci.2021228415610.3390/ijms22084156 33923817
     [Google Scholar]
  18. PalS.C. Méndez-SánchezN. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.World J. Gastroenterol.202329253999400810.3748/wjg.v29.i25.3999 37476582
     [Google Scholar]
  19. KayaE. YilmazY. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: A comparative review with nonalcoholic fatty liver disease.Ther. Adv. Endocrinol. Metab.20221310.1177/20420188221139650 36533185
     [Google Scholar]
  20. HuangS.C. SuH.J. KaoJ.H. TsengT.C. YangH.C. SuT.H. ChenP.J. LiuC.J. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease.Gut Liver202115345145810.5009/gnl20218 33431715
     [Google Scholar]
  21. ChowdhuryA.B. MehtaK.J. Liver biopsy for assessment of chronic liver diseases: A synopsis.Clin. Exp. Med.202223227328510.1007/s10238‑022‑00799‑z 35192111
     [Google Scholar]
  22. HuangJ. XueW. WangM. WuY. SinghM. ZhuY. KumarR. LinS. MAFLD criteria may overlook a subtype of patient with steatohepatitis and significant fibrosis.Diabetes Metab. Syndr. Obes.2021143417342510.2147/DMSO.S316096 34349535
     [Google Scholar]
  23. SchwenzerN.F. SpringerF. SchramlC. StefanN. MachannJ. SchickF. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.J. Hepatol.200951343344510.1016/j.jhep.2009.05.023 19604596
     [Google Scholar]
  24. SternC. CasteraL. Non-invasive diagnosis of hepatic steatosis.Hepatol. Int.2017111707810.1007/s12072‑016‑9772‑z 27783208
     [Google Scholar]
  25. ZhangY.N. FowlerK.J. HamiltonG. CuiJ.Y. SyE.Z. BalanayM. HookerJ.C. SzeverenyiN. SirlinC.B. Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging.Br. J. Radiol.20189110892017095910.1259/bjr.20170959 29722568
     [Google Scholar]
  26. PetzoldG. Role of ultrasound methods for the assessment of NAFLD.J. Clin. Med.20221115458110.3390/jcm11154581 35956196
     [Google Scholar]
  27. ContrerasD. González-RochaA. ClarkP. BarqueraS. Denova-GutiérrezE. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis.Ann. Hepatol.202328110087310.1016/j.aohep.2022.100873 36371077
     [Google Scholar]
  28. MaximosM. BrilF. Portillo SanchezP. LomonacoR. OrsakB. BiernackiD. SumanA. WeberM. CusiK. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.Hepatology201561115316010.1002/hep.27395 25145475
     [Google Scholar]
  29. SanyalD. MukherjeeP. RaychaudhuriM. GhoshS. MukherjeeS. ChowdhuryS. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes.Indian J. Endocrinol. Metab.201519559760110.4103/2230‑8210.163172 26425466
     [Google Scholar]
  30. HuangT.D. BeharyJ. ZekryA. Non‐alcoholic fatty liver disease: A review of epidemiology, risk factors, diagnosis and management.Intern. Med. J.20205091038104710.1111/imj.14709 31760676
     [Google Scholar]
  31. StefanN. HäringH.U. CusiK. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies.Lancet Diabetes Endocrinol.20197431332410.1016/S2213‑8587(18)30154‑2 30174213
     [Google Scholar]
  32. BergerD. DesaiV. JanardhanS. Con: Liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease.Clin. Liver Dis.201913411411610.1002/cld.740 31061705
     [Google Scholar]
  33. SumidaY. NakajimaA. ItohY. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J. Gastroenterol.201420247548510.3748/wjg.v20.i2.475 24574716
     [Google Scholar]
  34. MantovaniA. ScorlettiE. MoscaA. AlisiA. ByrneC.D. TargherG. Complications, morbidity and mortality of nonalcoholic fatty liver disease.Metabolism202011115417010.1016/j.metabol.2020.154170 32006558
     [Google Scholar]
  35. MännistöV.T. SalomaaV. FärkkiläM. JulaA. MännistöS. ErlundI. SundvallJ. LundqvistA. PerolaM. ÅbergF. Incidence of liver‐related morbidity and mortality in a population cohort of non‐alcoholic fatty liver disease.Liver Int.202141112590260010.1111/liv.15004 34219352
     [Google Scholar]
  36. WongG.L.H. Non‐invasive assessments for liver fibrosis: The crystal ball we long for.J. Gastroenterol. Hepatol.20183351009101510.1111/jgh.14103 29380413
     [Google Scholar]
  37. AnsteeQ.M. CasteraL. LoombaR. Impact of non-invasive biomarkers on hepatology practice: Past, present and future.J. Hepatol.20227661362137810.1016/j.jhep.2022.03.026 35589256
     [Google Scholar]
  38. AgbimU. AsraniS.K. Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers.Expert Rev. Gastroenterol. Hepatol.201913436137410.1080/17474124.2019.1579641 30791772
     [Google Scholar]
  39. MansourA.M.F. BayoumyE.M. ElGhandourA.M. El-TalkawyM.D. BadrS.M. AhmedA.E.M. Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease.Egyptian Liver Journal20201013310.1186/s43066‑020‑00044‑w
     [Google Scholar]
  40. LongM.T. GandhiS. LoombaR. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.Metabolism202011115425910.1016/j.metabol.2020.154259 32387227
     [Google Scholar]
  41. ChengxiL. RentaoL. WeiZ. Progress in non-invasive detection of liver fibrosis.Cancer Biol. Med.201815212413610.20892/j.issn.2095‑3941.2018.0018 29951337
     [Google Scholar]
  42. ThanapiromK. SuksawatamnuayS. TanpowpongN. ChaopathomkulB. SriphoosanaphanS. ThaimaiP. SrisoonthornN. TreeprasertsukS. KomolmitP. Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: A prospective study.Sci. Rep.2022121491310.1038/s41598‑022‑08955‑x 35318425
     [Google Scholar]
  43. PetroniM.L. BrodosiL. BugianesiE. MarchesiniG. Management of non-alcoholic fatty liver disease.BMJ2021372m474710.1136/bmj.m4747 33461969
     [Google Scholar]
  44. McPhersonS. StewartS.F. HendersonE. BurtA.D. DayC.P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut20105991265126910.1136/gut.2010.216077 20801772
     [Google Scholar]
  45. ValiY. LeeJ. BoursierJ. SpijkerR. LöfflerJ. VerheijJ. BrosnanM.J. BöcskeiZ. AnsteeQ.M. BossuytP.M. ZafarmandM.H. PavlidesM. LevickC. DuffinK. HydeC. BauerT. BedossaP. LeemingD. DalyA. HanfR. OrtizP. OresicM. SchuppanD. HanauerG. ChenY. ShumbayawondaE. BjerringP.N. ZwindermanK. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.J. Hepatol.202073225226210.1016/j.jhep.2020.03.036 32275982
     [Google Scholar]
  46. PatelK. SebastianiG. Limitations of non-invasive tests for assessment of liver fibrosis.JHEP Reports20202210006710.1016/j.jhepr.2020.100067 32118201
     [Google Scholar]
  47. CasteraL. Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics.Liver Int.202040S1Suppl. 1778110.1111/liv.14347 32077617
     [Google Scholar]
  48. Vilar-GomezE. ChalasaniN. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.J. Hepatol.201868230531510.1016/j.jhep.2017.11.013 29154965
     [Google Scholar]
  49. ParkC.C. NguyenP. HernandezC. BettencourtR. RamirezK. FortneyL. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology2017152598607
     [Google Scholar]
  50. GaiaS. CarenziS. BarilliA.L. BugianesiE. SmedileA. BrunelloF. MarzanoA. RizzettoM. Reliability of transient elastography for the detection of fibrosis in Non-Alcoholic Fatty Liver Disease and chronic viral hepatitis.J. Hepatol.2011541647110.1016/j.jhep.2010.06.022 20932598
     [Google Scholar]
  51. BerzigottiA. CasteraL. Update on ultrasound imaging of liver fibrosis.J. Hepatol.201359118018210.1016/j.jhep.2012.12.028 23333447
     [Google Scholar]
  52. NagarajanK. Efficacy of ultrasound elastography in characterizing focal liver lesions with histopathologic correlation.ChennaiMadras Medical College2019
     [Google Scholar]
  53. TapperE.B. LoombaR. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.Nat. Rev. Gastroenterol. Hepatol.201815527428210.1038/nrgastro.2018.10 29463906
     [Google Scholar]
  54. GrątK. GrątM. RowińskiO. Usefulness of different imaging modalities in evaluation of patients with non-alcoholic fatty liver disease.Biomedicines20208929810.3390/biomedicines8090298 32839409
     [Google Scholar]
  55. TrujilloM.J. ChenJ. RubinJ.M. GaoJ. Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review.Clin. Imaging202178223410.1016/j.clinimag.2021.02.039 33721575
     [Google Scholar]
  56. CobboldJ.F.L. PatelD. Taylor-RobinsonS.D. Assessment of inflammation and fibrosis in non‐alcoholic fatty liver disease by imaging‐based techniques.J. Gastroenterol. Hepatol.20122781281129210.1111/j.1440‑1746.2012.07127.x 22432836
     [Google Scholar]
  57. LoombaR. WolfsonT. AngB. HookerJ. BehlingC. PetersonM. ValasekM. LinG. BrennerD. GamstA. EhmanR. SirlinC. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study.Hepatology20146061920192810.1002/hep.27362 25103310
     [Google Scholar]
  58. SchaapmanJ.J. TushuizenM.E. CoenraadM.J. LambH.J. Multiparametric MRI in patients with nonalcoholic fatty liver disease.J. Magn. Reson. Imaging20215361623163110.1002/jmri.27292 32822095
     [Google Scholar]
  59. PermuttZ. LeT.A. PetersonM.R. SekiE. BrennerD.A. SirlinC. LoombaR. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD.Aliment. Pharmacol. Ther.2012361222910.1111/j.1365‑2036.2012.05121.x 22554256
     [Google Scholar]
  60. ThieleM. MadsenB.S. HansenJ.F. DetlefsenS. AntonsenS. KragA. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease.Gastroenterology201815451369137910.1053/j.gastro.2018.01.005 29317276
     [Google Scholar]
  61. LoombaR. AdamsL.A. Advances in non-invasive assessment of hepatic fibrosis.Gut20206971343135210.1136/gutjnl‑2018‑317593 32066623
     [Google Scholar]
  62. HalfonP. MunteanuM. PoynardT. FibroTest-ActiTest as a non-invasive marker of liver fibrosis.Gastroenterol. Clin. Biol.2008326Suppl. 1223910.1016/S0399‑8320(08)73991‑5 18973844
     [Google Scholar]
  63. Friedrich-RustM. RosenbergW. ParkesJ. HerrmannE. ZeuzemS. SarrazinC. Comparison of ELF, fibrotest and fibroscan for the non-invasive assessment of liver fibrosis.BMC Gastroenterol.201010110310.1186/1471‑230X‑10‑103 20828377
     [Google Scholar]
  64. ValiY. LeeJ. BoursierJ. SpijkerR. VerheijJ. BrosnanM. AnsteeQ. BossuytP. ZafarmandM. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: A systematic review and meta-analysis.J. Clin. Med.20211011241510.3390/jcm10112415 34072480
     [Google Scholar]
  65. BoursierJ. GuillaumeM. LeroyV. IrlèsM. RouxM. LannesA. FoucherJ. ZuberbuhlerF. DelabaudièreC. BarthelonJ. MichalakS. HiriartJ.B. PeronJ.M. GersterT. Le BailB. RiouJ. HunaultG. MerroucheW. ObertiF. PeladeL. FouchardI. BureauC. CalèsP. de LedinghenV. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.J. Hepatol.201971238939610.1016/j.jhep.2019.04.020 31102719
     [Google Scholar]
  66. OedaS. TakahashiH. ImajoK. SekoY. KobayashiT. OgawaY. MoriguchiM. YonedaM. AnzaiK. IrieH. SueokaE. AishimaS. KageM. ItohY. EguchiY. NakajimaA. Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison between M and XL probes.Hepatol. Res.202050783183910.1111/hepr.13508 32337818
     [Google Scholar]
  67. NewsomeP.N. SassoM. DeeksJ.J. ParedesA. BoursierJ. ChanW.K. YilmazY. CzernichowS. ZhengM.H. WongV.W.S. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD.A. EddowesP.J. GuhaI.N. CobboldJ.F. ParadisV. BedossaP. MietteV. Fournier-PoizatC. SandrinL. HarrisonS.A. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study.Lancet Gastroenterol. Hepatol.20205436237310.1016/S2468‑1253(19)30383‑8 32027858
     [Google Scholar]
  68. KumariB. KumarR. SharmaS. BanerjeeA. KumarV. KumarP. ChaudharyN. KumarS. RajK. Diagnostic accuracy of FIB-4 and FIB-5 scores as compared to fibroscan for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease.Cureus2021138e1762210.7759/cureus.17622 34646672
     [Google Scholar]
  69. AykutU.E. AkyuzU. YesilA. ErenF. GerinF. ErgelenR. CelikelC.A. YilmazY. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.Scand. J. Gastroenterol.201449111343134810.3109/00365521.2014.958099 25259621
     [Google Scholar]
  70. Van DijkA.M. ValiY. MakA.L. LeeJ. TushuizenM.E. ZafarmandM.H. AnsteeQ.M. BrosnanM.J. NieuwdorpM. BossuytP.M. HolleboomA.G. Systematic review with meta-analyses: Diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease.J. Clin. Med.20211013291010.3390/jcm10132910 34209858
     [Google Scholar]
  71. DincsesE. YilmazY. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.Eur. J. Gastroenterol. Hepatol.201527101149115310.1097/MEG.0000000000000409 26049712
     [Google Scholar]
  72. CardosoA.C. TovoC.V. LeiteN.C. El BachaI.A. CalçadoF.L. CoralG.P. SammarcoG.N. CravoC. Carvalho FilhoR.J. de Mello PerezR. LuizR.R. PariseE.R. Villela-NogueiraC.A. Validation and performance of FibroScan®-AST (fast) score on a Brazilian population with nonalcoholic fatty liver disease.Dig. Dis. Sci.202267115272527910.1007/s10620‑021‑07363‑x 35091842
     [Google Scholar]
  73. RavaioliF. DajtiE. MantovaniA. NewsomeP.N. TargherG. ColecchiaA. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: A systematic review and meta-analysis.Gut20237271399140910.1136/gutjnl‑2022‑328689 36599683
     [Google Scholar]
  74. SumidaY. YonedaM. TokushigeK. KawanakaM. FujiiH. YonedaM. ImajoK. TakahashiH. EguchiY. OnoM. NozakiY. HyogoH. KosekiM. YoshidaY. KawaguchiT. KamadaY. OkanoueT. NakajimaA. FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic.Life202111214310.3390/life11020143 33672864
     [Google Scholar]
  75. XuX. JiangL. WuC. PanL. LouZ. PengC. DongY. RuanB. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?J. Formos. Med. Assoc.2022121245446610.1016/j.jfma.2021.07.013 34325952
     [Google Scholar]
  76. DayJ.W. RosenbergW.M. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis.Br. J. Hosp. Med.2018791269469910.12968/hmed.2018.79.12.694 30526098
     [Google Scholar]
  77. ChenC. WangL. WuJ. LuM. YangS. YeW. GuanM. LiangM. ZouH. Circulating collagen metabolites and the enhanced liver fibrosis (ELF) score as fibrosis markers in systemic sclerosis.Front. Pharmacol.20221380570810.3389/fphar.2022.805708 35177989
     [Google Scholar]
  78. Maroto-GarcíaJ. Moreno ÁlvarezA. Sanz de PedroM.P. Buño-SotoA. GonzálezÁ. Serum biomarkers for liver fibrosis assessment.Advances in Laboratory Medicine202310.1515/almed‑2023‑0081
     [Google Scholar]
  79. LaurentS JenniferO CécileB CélineF VéroniqueM SebastianM Non-invasive assessment of liver fibrosis by vibration-controlled transient elastography (Fibroscan®).Liver biopsy2011
     [Google Scholar]
  80. RinaldiL. GiorgioneC. MormoneA. EspositoF. RinaldiM. BerrettaM. MarfellaR. RomanoC. Non-invasive measurement of hepatic fibrosis by transient elastography: A narrative review.Viruses2023158173010.3390/v15081730 37632072
     [Google Scholar]
  81. LoréeH. BastardC. MietteV. SandrinL. Vibration-guided transient elastography: A novel fibroscan® examination with improved guidance for liver stiffness measurement.Ultrasound Med. Biol.20204692193220610.1016/j.ultrasmedbio.2020.04.010 32536508
     [Google Scholar]
  82. CaoY. XiangL. QiF. ZhangY. ChenY. ZhouX. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.EClinicalMedicine20225110154710.1016/j.eclinm.2022.101547 35844772
     [Google Scholar]
  83. BraudeM. RobertsS. MajeedA. LubelJ. PrompenJ. DevA. SievertW. BloomS. GowP. KempW. Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease.Liver Int.2023431909910.1111/liv.15415 36050821
     [Google Scholar]
  84. OedaS. TanakaK. OshimaA. MatsumotoY. SueokaE. TakahashiH. Diagnostic accuracy of FibroScan and factors affecting measurements.Diagnostics2020101194010.3390/diagnostics10110940 33198092
     [Google Scholar]
  85. OedaS. TakahashiH. ImajoK. SekoY. OgawaY. MoriguchiM. YonedaM. AnzaiK. AishimaS. KageM. ItohY. NakajimaA. EguchiY. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: A multicenter prospective study.J. Gastroenterol.202055442844010.1007/s00535‑019‑01635‑0 31654131
     [Google Scholar]
  86. SalmiA. di FilippoL. FerrariC. FraraS. GiustinaA. Ultrasound and fibroscan® controlled attenuation parameter in patients with MAFLD: Head to head comparison in assessing liver steatosis.Endocrine202278226226910.1007/s12020‑022‑03157‑x 35980569
     [Google Scholar]
  87. YilmazY. KayaE. The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease.Hepatology Forum20234212
     [Google Scholar]
  88. EddowesP.J. SassoM. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD. GuhaI.N. CobboldJ.F. DeeksJ.J. ParadisV. BedossaP. NewsomeP.N. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology201915661717173010.1053/j.gastro.2019.01.042 30689971
     [Google Scholar]
  89. XuN. XieQ. LiJ. GaoY. LiX. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease.J. Int. Med. Res.202048210.1177/030006052090366732070159
     [Google Scholar]
  90. MikolasevicI. Lukenda ZankoV. JakopcicI. DomislovicV. MijicA. StevanovicT. DelijaB. BokunT. Dinjar KujundzicP. OstojicA. Filipec KanizajT. GrgurevicI. KrznaricZ. StimacD. TargherG. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements.J. Diabetes Complications202034310751210.1016/j.jdiacomp.2019.107512 31882273
     [Google Scholar]
  91. MikolasevicI. OrlicL. FranjicN. HauserG. StimacD. MilicS. Transient elastography (FibroScan ®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?World J. Gastroenterol.201622327236725110.3748/wjg.v22.i32.7236 27621571
     [Google Scholar]
  92. MussoG. GambinoR. CassaderM. PaganoG. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.Ann. Med.201143861764910.3109/07853890.2010.518623 21039302
     [Google Scholar]
  93. PaisR. LupşorM. PoantăL. SilaghiA. RusuM.L. BadeaR. DumitraşcuD.L. Liver biopsy versus noninvasive methods--fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: A review of the literature.Rom. J. Intern. Med.2009474331340 21179914
     [Google Scholar]
  94. DegosF. PerezP. RocheB. MahmoudiA. AsselineauJ. VoitotH. BedossaP. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study).J. Hepatol.20105361013102110.1016/j.jhep.2010.05.035 20850886
     [Google Scholar]
  95. MatthewsK. MacGilchristA. Coulter-SmithM. JonesJ. CetnarskyjR. A nurse‐led FibroScan ® outreach clinic encourages socially deprived heavy drinkers to engage with liver services.J. Clin. Nurs.2019283-465066210.1111/jocn.14660 30182502
     [Google Scholar]
  96. PatelK. WilderJ. Fibroscan.Clin. Liver Dis.2014459710110.1002/cld.407 30992931
     [Google Scholar]
  97. ArmstrongM.J. CorbettC. HodsonJ. MarwahN. ParkerR. HoulihanD.D. RoweI.A. HazlehurstJ.M. BrownR. HübscherS.G. MutimerD. Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice.Postgrad. Med. J.201389105868569210.1136/postgradmedj‑2012‑131640 23924687
     [Google Scholar]
  98. de LédinghenV. VergniolJ. Transient elastography (FibroScan).Gastroenterol. Clin. Biol.2008326Suppl. 1586710.1016/S0399‑8320(08)73994‑0 18973847
     [Google Scholar]
  99. MuellerS. SandrinL. Liver stiffness: A novel parameter for the diagnosis of liver disease.Hepat. Med.20102496710.2147/HMER.S7394 24367208
     [Google Scholar]
  100. MatthewsK. Advancing nursing practice in the field of hepatology through a prospective observational research study implementing innovative screening for liver disease in a community alcohol service with a portable FibroScan® device.EdinburghQueen Margaret University2019
     [Google Scholar]
  101. WongG.L.H. Update of liver fibrosis and steatosis with transient elastography (Fibroscan).Gastroenterol. Rep.201311192610.1093/gastro/got007 24759663
     [Google Scholar]
  102. RajakannuM. Impact of Fibroscan in the management of liver tumors.Université Paris Saclay2017
     [Google Scholar]
  103. MortimoreG. FibroScan: Assessing cirrhosis and advanced fibrosis with vibration-controlled transient elastography.Gastrointest. Nurs.201614Sup10S10S1510.12968/gasn.2016.14.Sup10.S10
     [Google Scholar]
  104. AubéC. BazeriesP. LebigotJ. CartierV. BoursierJ. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance.Diagn. Interv. Imaging201798645546810.1016/j.diii.2017.03.003 28461073
     [Google Scholar]
  105. BaranovaA. LalP. BirerdincA. YounossiZ.M. Non-Invasive markers for hepatic fibrosis.BMC Gastroenterol.20111119110.1186/1471‑230X‑11‑91 21849046
     [Google Scholar]
  106. AugustinS. AhmedA. AlkhouriN. CanbayA. CorlessL. NakajimaA. OkanoueT. PettaS. RatziuV. TsochatzisE.A. WongV.W.S. Romero-GómezM. Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: Considerations for best practice.J. Gastrointestin. Liver Dis.202029223524510.15403/jgld‑775 32530991
     [Google Scholar]
  107. PennisiG. EneaM. PandolfoA. CelsaC. AntonucciM. CiccioliC. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD.Clinical Gastroenterology and Hepatology20232112931302
     [Google Scholar]
  108. SolomonA. NegreaM.O. CipăianC.R. BoiceanA. MihailaR. ReziC. Interactions between metabolic syndrome, MASLD, and arterial stiffening: A single-center cross-sectional study.Healthcare202311192696
     [Google Scholar]
  109. ShiY. FanJ.G. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.Clin. Mol. Hepatol.202329Suppl.S228S24310.3350/cmh.2022.0401 36521452
     [Google Scholar]
  110. MiuraK. HayashiH. KamadaY. FujiiH. TakahashiH. OedaS. IwakiM. KawaguchiT. TomitaE. YonedaM. TokushigeA. UedaS. AishimaS. SumidaY. NakajimaA. OkanoueT. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease.Hepatol. Res.2023531097898810.1111/hepr.13938 37353881
     [Google Scholar]
  111. SanyalA.J. FoucquierJ. YounossiZ.M. HarrisonS.A. NewsomeP.N. ChanW.K. YilmazY. De LedinghenV. CostentinC. ZhengM.H. Wai-Sun WongV. ElkhashabM. HussR.S. MyersR.P. RouxM. LabourdetteA. DestroM. Fournier-PoizatC. MietteV. SandrinL. BoursierJ. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.J. Hepatol.202378224725910.1016/j.jhep.2022.10.034 36375686
     [Google Scholar]
  112. GjiniK. ArmandiA. CavigliaG.P. RossoC. CastelnuovoG. Perez-Diaz-Del-CampoN. RibaldoneD.G. D’AmatoD. AbdulleA. SaraccoG.M. BugianesiE. The use of AGILE 3+ and AGILE 4 for the prediction of advanced fibrosis and cirrhosis in patients with Non-Alcoholic Fatty Liver Disease.Dig. Liver Dis.202355S31S3210.1016/j.dld.2023.01.060
     [Google Scholar]
  113. MiuraK. MaedaH. MorimotoN. WatanabeS. TsukuiM. TakaokaY. NomotoH. GokaR. KotaniK. YamamotoH. Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities.World J. Gastrointest. Pathophysiol.20221339610610.4291/wjgp.v13.i3.96 35720167
     [Google Scholar]
  114. CastéraL. Fournier-PoizatC. FoucquierJ. KjaerM. KrarupN. MietteV. NygårdS.B. PatelA.S. SandrinL. SchattenbergJ. Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: Analysis of data from a randomised placebo-controlled trial of semaglutide.J. Hepatol.202378S817S81810.1016/S0168‑8278(23)02279‑1
     [Google Scholar]
  115. TangL.J. LiG. EslamM. ZhuP.W. ChenS.D. LeungH.H.W. HuangO.Y. WongG.L.H. ZhouY.J. KarsdalM. LeemingD.J. JiangP. WangC. YuanH.Y. ByrneC.D. TargherG. GeorgeJ. WongV.W.S. ZhengM.H. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD.Hepatol. Int.202317119020110.1007/s12072‑022‑10420‑w 36152131
     [Google Scholar]
  116. PennisiG. EneaM. FalcoV. AithalG.P. PalaniyappanN. YilmazY. BoursierJ. CassinottoC. de LédinghenV. ChanW.K. MahadevaS. EddowesP. NewsomeP. KarlasT. WiegandJ. WongV.W.S. SchattenbergJ.M. LabenzC. KimW. LeeM.S. Lupsor-PlatonM. CobboldJ.F.L. FanJ.G. ShenF. StauferK. TraunerM. StauberR. NakajimaA. YonedaM. BugianesiE. YounesR. GaiaS. ZhengM.H. CammàC. AnsteeQ.M. MózesF.E. PavlidesM. PettaS. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.Hepatology202378119521110.1097/HEP.0000000000000351 36924031
     [Google Scholar]
  117. TincopaM.A. LoombaR. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Lancet Gastroenterol. Hepatol.20238766067010.1016/S2468‑1253(23)00066‑3 37060912
     [Google Scholar]
  118. BoursierJ. RouxM. SanyalA.J. Agile3+ and Agile4: Two diagnostic scores that synergize for the prognostic assessment in NAFLD.J. Hepatol.2023
     [Google Scholar]
  119. SunC. GohG.B-B. ChowW-C. ChanW-K. WongG.L-H. SetoW-K. Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease.Hepatobiliary Pancreat. Dis. Int.2023 37620227
     [Google Scholar]
  120. YilmazY. ToramanA.E. AlpC. DoğanZ. KeklikkiranC. StepanovaM. YounossiZ. Impairment of patient‐reported outcomes among patients with non‐alcoholic fatty liver disease: A registry‐based study.Aliment. Pharmacol. Ther.202357221522310.1111/apt.17301 36369643
     [Google Scholar]
  121. PennisiG. EneaM. PandolfoA. CiccioliC. InfantinoG. ParisiS. TuloneA. Di MarcoV. CraxìA. CammàC. PettaS. AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease.Dig. Liver Dis.202254S17S1810.1016/j.dld.2022.01.033
     [Google Scholar]
  122. FerreiraL.F. MânicaM. Villela NogueiraC. TovoC.V. Patients with uncertain advanced fibrosis and cirrhosis diagnosis by Agile3+ and Agile4 scores cannot be excluded in validation studies.Hepatol. Res.2023 38041561
     [Google Scholar]
  123. AlkhouriN. AlmomaniA. LeP. PayneJ.Y. AsaadI. PolancoP. The prevalence of nonalcoholic steatohepatitis (NASH)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3+ and AGILE 4+ scores: Analysis of the NHANES 2017-2018 cycle.Am. J. Gastroenterol.20231124581587
     [Google Scholar]
  124. LeffP. PolancoP. ChathaY. GargP. LantzK.A. RamanA. Tu1311: External validation of the agile3+ score as a predictor of advanced fibrosis in a cohort of us adults with biopsyproven nafld.Gastroenterology2022162S-1271
     [Google Scholar]
  125. LiguoriA. ZoncapèM. RoccarinaD. VicecontiN. SciarraA. BeschiR. PratL.I. MantovaniA. ClancyJ. GoyaleA. GriecoA. MieleL. TsochatzisE.A. Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced chronic liver disease (cACLD) in NAFLD patients.Dig. Liver Dis.202355S15S1610.1016/j.dld.2023.01.028
     [Google Scholar]
  126. OedaS. SekoY. HayashiH. AraiT. IwakiM. YonedaM. ShimaT. NotsumataK. IkegamiT. FujiiH. ToyodaH. MiuraK. MorishitaA. KawataK. TomitaK. KawanakaM. IsodaH. YamaguchiK. FukushimaH. KamadaY. SumidaY. AishimaS. ItohY. OkanoueT. NakajimaA. TakahashiH. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.Hepatol. Res.202353648949610.1111/hepr.13890 36807720
     [Google Scholar]
  127. RomeroA. RomeroJ. NguyenN. OniyideO. SanchezJ. EgwimC. S1570 utility of novel fibroscan-based scores in the diagnosis of advanced fibrosis in nonalcoholic fatty liver disease.Am. J. Gastroenterol.2023118S118610.14309/01.ajg.0000955920.50337.b9
     [Google Scholar]
  128. BoursierJ. RouxM. CostentinC. ChaigneauJ. Fournier-PoizatC. TrylesinskiA. CanivetC.M. MichalakS. Le BailB. ParadisV. BedossaP. SturmN. de LedinghenV. BarthelonJ. BoursierJ. CalesP. CanivetC. DecaensT. DelamarreA. HermabessiereP. Irles-DepéM. de LedinghenV. HilleretM-N. Fouchard-HubertI. LannesA. Le BailB. MoalV. ObertiF. AllisonM. AnsteeQ.M. CobboldJ.F. DeeksJ.J. EddowesP.J. GuhaI.N. SheridanD. TsochatzisE. NewsomeP.N. Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests.Nat. Commun.2023141521910.1038/s41467‑023‑40328‑4 37633932
     [Google Scholar]
  129. TaruV. TaruM.G. PetrushevB. IoanaR. StefanescuH. FodorA. IgnatM.D. PetraF. Nicoara-FarcauO. PlatonM. ProcopetB. Recently validated non-invasive tests for liver fibrosis assessment have great performance in identifying NASH patients at risk for decompensation.J. Hepatol.202378S295S29610.1016/S0168‑8278(23)00887‑5
     [Google Scholar]
  130. NakatsukaT. TateishiR. SatoM. FujishiroM. KoikeK. Agile scores are a good predictor of liver-related events in patients with NAFLD.J. Hepatol.2023793e126e12710.1016/j.jhep.2023.02.029 36870612
     [Google Scholar]
  131. NoureddinM. MenaE. VuppalanchiR. SamalaN. WongM. PachecoF. PolancoP. SakkalC. AntaramianA. ChangD. NoureddinN. KohliA. HarrisonS.A. GawriehS. AlkhouriN. TruongE. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: Independent validation of the Agile 3+ and 4 scores.Hepatol. Commun.202375710.1097/HC9.0000000000000055 37141504
     [Google Scholar]
  132. AroraU. GoyalR.M. TehK.K.J. PeiY. GohG.B.B. LinS. KumarR. BiswasS. VaishnavM. SwaroopS. PathakP. SheikhS. BharadiyaV. ElhenceA. GamanagattiS. YadavR. DasP. AggarwalS. ChoudharyN. AnirvanP. SinghS.P. DeA. DusejaA. Shalimar, Poor performance of non-invasive tests for advanced fibrosis in nonalcoholic fatty liver disease: A multicentric Asian study.Dig. Dis. Sci.202368124485449810.1007/s10620‑023‑08085‑y 37733130
     [Google Scholar]
  133. DalbeniA. LombardiR. HenriqueM. ZoncapèM. PennisiG. PettaS. Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.Hepatology2023101097 38088890
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906302851240604042954
Loading
Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease: Detecting Advanced Fibrosis based on Reported Liver Stiffness Measurement in FibroScan and Laboratory Findings
Int J Gastroenterol Hepatol Dis 3, E270624231398 (2024); https://doi.org/10.2174/0126662906302851240604042954
/content/journals/ijghd/10.2174/0126662906302851240604042954
/content/journals/ijghd/10.2174/0126662906302851240604042954
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): accuracy; Area under curve; assessment; elasticity imaging techniques; liver cirrhosis; noninvasive tools; transient elastography

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test